GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic

Detailed summary
First-in-human trial to evaluate the potential for rapid, deep and selective IgG4 removal Healthy subject data expected in the first half of 2027 to support advancement into a…
First-in-human trial to evaluate the potential for rapid, deep and selective IgG4 removal
Healthy subject data expected in the first half of 2027 to support advancement into a patient trial in multiple IgG4-driven autoimmune diseases
NEWTON, Mass. and WÄDENSWIL, Switzerland, Nov. 16, 2026 /PRNewswire/ -- GlycoEra, a biotechnology company pioneering precision immunology through the selective removal of disease-driving proteins, today announced that it has initiated dosing of healthy subjects in a Phase 1a clinical trial of GE8820, the first IgG4-selective extracellular protein degrader to enter clinical development. GE8820 is designed to rapidly, deeply and selectively remove disease-driving IgG4 antibodies while preserving other protective immunoglobulins.
"Not all protein degraders are created equal. We believe the ability to remove disease-driving proteins rapidly, deeply and selectively will define the leaders in this field," said Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra. "That's what we've engineered our platform to deliver. With GE8820 now in the clinic as the first IgG4-selective degrader, we're taking an important step toward demonstrating the potential of our approach to redefine treatment for patients with serious autoimmune diseases."
The Phase 1a trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of GE8820 in healthy subjects through single ascending dose (SAD) and planned multiple ascending dose (MAD) evaluations, with intravenous and subcutaneous routes of administration.
In a nonhuman primate study, a single intravenous dose of GE8820 achieved greater than 95% depletion of circulating human IgG4, with maximum depletion in less than a day after dosing. Because IgG4 levels are comparable in healthy subjects and patients with certain IgG4-driven autoimmune diseases, the Phase 1a trial is expected to provide insights into the speed and depth of IgG4 reduction and inform dose selection for subsequent patient…
G…
Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)
